Recent Updates
Recently added Catalysts

Granulocyte transfusions

Phase 3

Neutropenia | Monoclonal antibody | Hematology |Elevance Health, Inc.|Last Updated: Apr 17, 2015

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLEDDMC
Total Trials1
Total Enrollment114

FDA Designations

No designations recorded

Clinical trial landscape

Granulocyte transfusions · 1 trial · 2 indications

Phase 3 1
NCT00627393Safety and Effectiveness of Granulocyte Transfusions in Resolving Infection in People With Neutropenia (The RING Study)Neutropenia
COMPLETED114 Analytics
PHASE3COMPLETED
Safety and Effectiveness of Granulocyte Transfusions in Resolving Infection in People With Neutropenia (The RING Study)
NeutropeniaUnlock trial analytics

Study Endpoints

Primary Endpoints

Percentage of Participants Who Are Alive at 42 Days After Treatment and Have Had Microbial Response
Measured at Day 42

Microbial response was defined as follows: * A negative blood culture test at 42 days after randomization for subjects with fungemia (candidemia or fusariosis) or bacteremia. * Improvement of signs and symptoms of infectious disease (complete or partial response) at 42 days after randomization.

Secondary Endpoints

Alloimmunization, Defined as the Appearance of Anti-human Leukocyte Antigen (HLA) or Antineutrophil Antibodies
Measured at Days 14 and 42
Serious Granulocyte Transfusion Reactions, Including Febrile, Allergic, and Pulmonary Reactions (Transfusion Arm Only)
Measured within 6 hours after end of transfusion
Graft Versus Host Disease Among Recipients of Allogeneic Stem Cell Transplantation
Measured at Day 42
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingSINGLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
1EXPERIMENTALParticipants will receive granulocyte transfusions in addition to standard antimicrobial therapy
2ACTIVE_COMPARATORParticipants will receive standard antimicrobial therapy alone
3OTHERParticipants will donate granulocytes after receiving a combination of two drugs, G-CSF and dexamethasone

Interventions

NameTypeDescription
Standard antimicrobial therapyDRUGAntimicrobial therapy is broadly defined as therapy within the standard of care for a particular infection and should be consistent within a given institution. Participants will undergo the recommended therapy for specific infections for 42 days.
Granulocyte transfusionsBIOLOGICALParticipants will receive one granulocyte transfusion per day until one of the following occurs: recovery from neutropenia, life-threatening toxicity, resolution or improvement of infection, or Day 42 after treatment. Granulocyte content of each transfusion is targeted to be at least 4 x 10\^10 per collection (or proportionately less for participants less than 30 kg in weight).
G-CSF/dexamethasoneDRUGTwelve hours before each donation, participants will be injected with G-CSF and will take one dose of dexamethasone by mouth.
Apheresis machineDEVICEParticipants will undergo a procedure using an apheresis machine for granulocyte collection. The procedure will last 3 to 4 hours and will involve the drawing of blood from each arm, the separation of granulocytes from the red cells and plasma in the machine, and the return of the red cells and plasma to the participants.
Unlock Study Design Details

Eligibility Criteria

SexALL
Healthy VolunteersNo
Study Sites13

Inclusion Criteria: * Severe neutropenia (Absolute Neutrophil Count \< 500/mm\^3) due to marrow failure caused by underlying disease or therapy * Must have one of the following: fungemia; bacteremia; proven or presumptive invasive tissue bacterial infection; or proven, probable, or presumptive inva...

Countries:United States
Unlock Eligibility Criteria